[go: up one dir, main page]

MXPA05008838A - Formulaciones de absorcion acelerada del agonista selectivo de la 5-ht. - Google Patents

Formulaciones de absorcion acelerada del agonista selectivo de la 5-ht.

Info

Publication number
MXPA05008838A
MXPA05008838A MXPA05008838A MXPA05008838A MXPA05008838A MX PA05008838 A MXPA05008838 A MX PA05008838A MX PA05008838 A MXPA05008838 A MX PA05008838A MX PA05008838 A MXPA05008838 A MX PA05008838A MX PA05008838 A MXPA05008838 A MX PA05008838A
Authority
MX
Mexico
Prior art keywords
rapid absorption
selective
agonist formulations
incorporated
agonist
Prior art date
Application number
MXPA05008838A
Other languages
English (en)
Inventor
Paul Maes
Original Assignee
Biovail Lab Int Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovail Lab Int Srl filed Critical Biovail Lab Int Srl
Publication of MXPA05008838A publication Critical patent/MXPA05008838A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invencion proporciona una composicion farmaceutica de absorcion acelerada que comprende una cantidad efectiva de al menos un agonista selectivo de la 5-HT, al menos un adyuvante de la esferonizacion y al menos un mejorador de la solubilidad. La composicion de la invencion se incorpora en microparticulas, las cuales pueden tener sabor enmascarado y posteriormente se incorporan en una variedad de formas de dosificacion para la administracion a un paciente que sufre de migrana.
MXPA05008838A 2003-02-19 2004-02-18 Formulaciones de absorcion acelerada del agonista selectivo de la 5-ht. MXPA05008838A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44774103P 2003-02-19 2003-02-19
PCT/US2004/004572 WO2004073632A2 (en) 2003-02-19 2004-02-18 Rapid absorption selective 5-ht agonist formulations

Publications (1)

Publication Number Publication Date
MXPA05008838A true MXPA05008838A (es) 2006-02-17

Family

ID=32908492

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05008838A MXPA05008838A (es) 2003-02-19 2004-02-18 Formulaciones de absorcion acelerada del agonista selectivo de la 5-ht.

Country Status (8)

Country Link
US (1) US20040162333A1 (es)
EP (1) EP1594470A4 (es)
JP (1) JP2006523620A (es)
AU (1) AU2004212976A1 (es)
CA (1) CA2514875A1 (es)
MX (1) MXPA05008838A (es)
NO (1) NO20054015L (es)
WO (1) WO2004073632A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1615635A1 (en) * 2003-04-11 2006-01-18 Pfizer Limited Pharmaceutical combination comprising eletriptan and sodium bicarbonate
WO2005061088A1 (en) * 2003-12-22 2005-07-07 Finlay Warren H Powder formation by atmospheric spray-freeze drying
US20070269510A1 (en) * 2004-09-29 2007-11-22 Sudarshan Nimbalkar Solid Unit Dosage Forms of 5-Ht1 Agonist
GB0501809D0 (en) * 2005-01-28 2005-03-09 Pharmakodex Ltd Anti-migraine formulations
CN102716490A (zh) * 2005-09-01 2012-10-10 卫材R&D管理有限公司 药物组合物的崩解性的改善方法
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20090136570A1 (en) * 2006-01-20 2009-05-28 Bhagwant Rege Taste-Masked Tablets and Granules
WO2007095716A1 (en) * 2006-02-23 2007-08-30 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
TW200835527A (en) * 2006-12-26 2008-09-01 Shionogi & Co Orally disintegrating tablet and bitter taste-masked formulation comprising risperidone
WO2008120548A2 (ja) 2007-03-13 2008-10-09 Dainippon Sumitomo Pharma Co., Ltd. 口腔内崩壊錠
WO2009064458A2 (en) 2007-11-13 2009-05-22 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
JP2011518881A (ja) * 2008-04-28 2011-06-30 ゾゲニクス インコーポレーティッド 片頭痛の治療のための製剤
BRPI0914164B1 (pt) * 2008-06-20 2019-04-30 Merck Patent Gmbh Comistura para produção de comprimidos de desintegração rápida em um processo de formação de comprimido direto, seus usos, e formulações de comprimido
EP2440210A4 (en) 2009-06-12 2014-01-29 Meritage Pharma Inc METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES
EP2451447B1 (de) * 2009-07-10 2017-10-11 Merck Patent GmbH Wasserarmes tablettierhilfsmittel und verfahren zu seiner herstellung
JP6038651B2 (ja) * 2009-07-10 2016-12-07 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 錠剤を製造するための組成物の調製方法
US8906949B2 (en) 2010-05-21 2014-12-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Orally disintegrating tablets of zolmitriptan and process for preparing the same
US8901159B2 (en) 2010-07-01 2014-12-02 Allergan, Inc. Inhibition of inflammation by simultaneous blockade of multiple prostanoid receptors
JP6021805B2 (ja) 2011-04-18 2016-11-09 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
AR089857A1 (es) * 2012-02-02 2014-09-24 Glaxosmithkline Llc Comprimido antiacido para refrescar el aliento
BR112015009004A8 (pt) 2012-12-21 2021-07-20 Eisai R&D Man Co Ltd forma amorfa de derivado de quinolina e método de produção da mesma
US10517861B2 (en) 2013-05-14 2019-12-31 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
JP6659554B2 (ja) 2014-08-28 2020-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 高純度キノリン誘導体およびその製造方法
LT3263106T (lt) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. Chinolino darinių kartumo sumažinimo būdas
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
AU2016279474B2 (en) 2015-06-16 2021-09-09 Eisai R&D Management Co., Ltd. Anticancer agent
WO2017004501A1 (en) 2015-07-02 2017-01-05 Civitas Therapeutics, Inc. Triptan powders for pulmonary delivery
SG11201801083UA (en) 2015-08-20 2018-03-28 Eisai R&D Man Co Ltd Tumor therapeutic agent
CN110072528B (zh) 2017-02-08 2022-04-26 卫材R&D管理有限公司 治疗肿瘤的药物组合物
KR20200013644A (ko) 2017-05-16 2020-02-07 에자이 알앤드디 매니지먼트 가부시키가이샤 간세포 암종의 치료
CN119499195A (zh) * 2024-11-26 2025-02-25 青岛国信制药有限公司 一种快速吸收琥珀酸呋罗曲坦片及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077822A (en) * 1993-09-14 2000-06-20 Dumex-Alpharma A/S Drug salts
GB9325445D0 (en) * 1993-12-13 1994-02-16 Cortecs Ltd Pharmaceutical formulations
EP0744941B1 (en) * 1994-02-16 2003-06-04 Abbott Laboratories Process for preparing fine particle pharmaceutical formulations
US5849322A (en) * 1995-10-23 1998-12-15 Theratech, Inc. Compositions and methods for buccal delivery of pharmaceutical agents
CA2281642C (en) * 1997-03-03 2008-02-05 F. Hoffmann-La Roche Ag Substituted 2,4-diaminopyrimidines
US5869098A (en) * 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
US6013280A (en) * 1997-10-07 2000-01-11 Fuisz Technologies Ltd. Immediate release dosage forms containing microspheres
WO1999021534A1 (en) * 1997-10-27 1999-05-06 Merck Patent Gmbh Solid state solutions and dispersions of poorly water soluble drugs
US6270804B1 (en) * 1998-04-03 2001-08-07 Biovail Technologies Ltd. Sachet formulations
US6117452A (en) * 1998-08-12 2000-09-12 Fuisz Technologies Ltd. Fatty ester combinations
AU5397300A (en) * 1999-06-02 2000-12-28 Hexal Ag Pharmaceutical composition for intranasal use of active substances that are insoluble and/or hardly soluble in water
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AU2001279284A1 (en) * 2000-07-05 2002-01-14 Capricorn Pharma, Inc Rapid-melt semi-solid compositions, methods of making same and methods of using same
JP2002037745A (ja) * 2000-07-25 2002-02-06 ▲高▼田 ▲寛▼治 水溶性の難・低吸収性薬物のバイオアベイラビリティ改善技術
US6706724B2 (en) * 2000-12-21 2004-03-16 Nitromed, Inc. Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use
FR2821745B1 (fr) * 2001-03-09 2004-07-02 Ethypharm Lab Prod Ethiques Granules et granules enrobes au gout masque

Also Published As

Publication number Publication date
JP2006523620A (ja) 2006-10-19
AU2004212976A1 (en) 2004-09-02
EP1594470A4 (en) 2007-10-17
NO20054015L (no) 2005-09-16
EP1594470A2 (en) 2005-11-16
WO2004073632A2 (en) 2004-09-02
WO2004073632A3 (en) 2004-11-18
US20040162333A1 (en) 2004-08-19
NO20054015D0 (no) 2005-08-30
CA2514875A1 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
MXPA05008838A (es) Formulaciones de absorcion acelerada del agonista selectivo de la 5-ht.
WO2005041925A3 (en) Compositions and dosage forms for enhanced absorption
DK1663194T3 (da) Anvendelse af SAHA til behandling af mesotheliom
WO2005018565A3 (en) Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof
DK1317419T3 (da) Cyanophenoxycarboxylsyre-forbindelser og sammensætninger til at levere aktive midler
MX2009003372A (es) Formas de dosificacion de pelicula no mucoadhesiva.
AU2003301190A1 (en) Administration of capsaicinoids
UY27598A1 (es) Composiciones farmacéuticas de derivados de taxano oralmente activos que tienen biodisponibilidad mejorada
EP1708685A4 (en) GALENIC FORMS OF EFFERVESCENT ORAL OPIATES AND METHODS OF ADMINISTERING OPIATES
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
NO20043367L (no) Oralt farmasoytisk preparat
EA200300183A1 (ru) Новое сочетание агониста (5-th2) и антагониста (5-ht6) серотонина в качестве фармацевтической композиции
EA200500985A1 (ru) Твердая лекарственная форма для перорального применения
DK1559431T3 (da) Farmaceutisk sammensætning til thrombinpeptidderivater
MY133503A (en) Selective iglur5 receptor antagonists for the treatment of migrane
MXPA03010054A (es) Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos.
MXPA04005420A (es) Composicion farmaceutica que comprende un agonista de receptor de 5ht1.
EA200600603A1 (ru) Оральная система доставки лекарственного препарата
EP1064966A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
EA200501697A1 (ru) Дозируемая форма, содержащая пантопразол в качестве активного ингредиента
MX2007005238A (es) Una composicion veterinaria transmucosal que comprende detomidina.
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
NO20061236L (no) Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og paratyroidhoziiton
WO2004069187A3 (en) Drug formulation and delivery using crystalline methylated cyclodextrins

Legal Events

Date Code Title Description
FA Abandonment or withdrawal